SGLT2 Inhibitor Use After Takotsubo Syndrome Linked to Lower Mortality
Early initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors after Takotsubo syndrome was associated with significantly lower all-cause mortality in a large real-world U.S. study, although reductions in cardiovascular complications were not observed. Using the TriNetX U.S. Collaborative Network, researchers identified adults diagnosed with Takotsubo syndrome between 2015 and 2025 and compared […]